Manulife Singapore has partnered with oncology treatment company Guardant to provide its customers access to the Guardant360 liquid biopsy test, according to a company release on Tuesday.
The company has also teamed up with AMILI which provides advanced gut microbiome screening.
The Guardant360 test carries out genomic profiling of advanced solid cancers and identifies biomarkers through blood samples.
Patients can see their results within seven days.
Through the partnership with AMILI, Manulife will be able provide its customers with personalized insights to improve their immunity, nutrition and brain health.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments